Ontada - Bridging Oncology and Data

Bridging the gap between practice and evidence

Ontada, whose name is a combination of “oncology” and “data,” was formed with the vision that transforming cancer care requires speed. Our commitment is to provide the most current evidence in oncology treatment so insights can be generated faster.

A group of circles in the shape of a spiral

Always cutting edge. Always ON. Trust us to keep you ahead of the curve

Our data sets us apart, but our connections set us ahead. Always ON is our promise to be your oncology bellwether, alerting you to changes in the oncology ecosystem, like how treatment and testing is impacted as the standard of care changes. With our finger on the pulse of community oncology, we can provide you with the most up-to-date insights and strategies to stay ahead in the ever-changing landscape of oncology. We’re committed to providing the most accurate and relevant information to guide your decision-making and drive success in the oncology market.

Ontada's history

As oncology care evolved, McKesson saw the need for a transformative, integrated approach using data, insights, and research. Ontada was created to develop a connected ecosystem that enhances care quality and reduces costs through efficient data utilization.

2024

Ontada collaborates with Microsoft to transform unstructured oncology data with Azure OpenAI Technology
Ontada collaborates with Datavant to enable faster access to market-leading oncology insights
Genospace, a precision medicine platform, unites with Ontada to transform cancer care through biomarker-driven therapies
ASCO’s Living Guidelines reference Ontada’s MYLUNG Consortium research on biomarkers

2023

FDA selects Ontada to investigate the natural history of rare cancers
McKesson designated by CMS as 2023 Qualified Clinical Data Registry, enabling iKnowMed users to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission, and minimizing administrative burden

2022

Investigators from US Oncology Research, The US Oncology Network, and Ontada present data highlighting key advances and insights at the 2022 American Society of Clinical Oncology Annual Meeting
New MYLUNG consortium research demonstrates remote pharmacist intervention significantly increases clinical trial enrollments in community oncology setting
BeiGene announces strategic alliance with Ontada to improve U.S. community oncology care

2021

MYLUNG study launches, aiming to advance use of precision medicine for metastatic non-small cell lung cancer patients
Ontada’s Clear Value Plus provides 800,000th chemotherapy treatment decision
First phase results of MYLUNG consortium provide historical view of biomarker testing patterns and identify data gaps for ongoing prospective research
Ontada signs strategic agreement with Merck to facilitate the development of data-driven insights to impact quality of cancer care
Ontada launches HOPE Studies, empowering oncologists to leverage real-world data and address healthcare disparities
US Oncology Research, The US Oncology Network, and ontada announce data presentations across areas of critical need at 2021 American Society of Hematology Annual Meeting and Exposition

2020

Biomarker Test Guidelines are added to iKnowMed EHR to support precision medicine. This capability suggests molecular tests by disease type along with vetted laboratory vendors to help physicians make informed decisions on the most personalized and effective ways to treat cancer for each patient.
Ontada is launched. Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer.
Amgen and McKesson launch strategic agreement to advance cancer innovation in communities

2019

McKesson announces that it is participating in Phase II of the Friends of Cancer Research (Friends) Real-World Evidence (RWE) pilot project to advance the understanding and inform future uses of RWE

2018

Providers using iKnowMed EHR are eligible for incentive payments under Merit-Based Incentive Payments System (MIPS)
McKesson launches Data, Evidence and Insights, a part of the new McKesson Life Sciences portfolio designed to support biopharma clinical and commercial strategy development

2017

McKesson expands its agreement with the NCCN, adding five additional disease states to Value Pathways
For the first time, real-world data (RWD) from McKesson’s iKnowMed EHR was part of a regulatory approval in oncology. McKesson's real-world evidence study was key in the FDA's approval of a new treatment for a rare skin cancer called metastatic Merkel Cell Carcinoma (mMCC)

2016

McKesson purchases Vantage Oncology, LLC, a leading national provider of radiation oncology, medical oncology, and integrated cancer care, and Biologics, Inc., an oncology pharmacy services company, creating a more expansive suite of offerings in the oncology space
McKesson announces a comprehensive solution to support community-based oncology practices participating in The Center for Medicare and Medicaid Innovation’s (CMMI) Oncology Care Model (OCM)

2014

Clear Value Plus is introduced, presenting Value Pathways powered by NCCN and NCCN Guidelines within the clinical workflow. This move offers integrated financial information, real-time reporting and benchmarking, and the ability to interface with an EHR
The first conversion of an iKnowMed Generation 1 customer to the iKnowMed Generation 2 platform occurs

Ontada collaborates with Microsoft to transform unstructured oncology data with Azure OpenAI Technology
Ontada collaborates with Datavant to enable faster access to market-leading oncology insights
Genospace, a precision medicine platform, unites with Ontada to transform cancer care through biomarker-driven therapies
ASCO’s Living Guidelines reference Ontada’s MYLUNG Consortium research on biomarkers

FDA selects Ontada to investigate the natural history of rare cancers
McKesson designated by CMS as 2023 Qualified Clinical Data Registry, enabling iKnowMed users to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission, and minimizing administrative burden

Investigators from US Oncology Research, The US Oncology Network, and Ontada present data highlighting key advances and insights at the 2022 American Society of Clinical Oncology Annual Meeting
New MYLUNG consortium research demonstrates remote pharmacist intervention significantly increases clinical trial enrollments in community oncology setting
BeiGene announces strategic alliance with Ontada to improve U.S. community oncology care

MYLUNG study launches, aiming to advance use of precision medicine for metastatic non-small cell lung cancer patients
Ontada’s Clear Value Plus provides 800,000th chemotherapy treatment decision
First phase results of MYLUNG consortium provide historical view of biomarker testing patterns and identify data gaps for ongoing prospective research
Ontada signs strategic agreement with Merck to facilitate the development of data-driven insights to impact quality of cancer care
Ontada launches HOPE Studies, empowering oncologists to leverage real-world data and address healthcare disparities
US Oncology Research, The US Oncology Network, and ontada announce data presentations across areas of critical need at 2021 American Society of Hematology Annual Meeting and Exposition

Biomarker Test Guidelines are added to iKnowMed EHR to support precision medicine. This capability suggests molecular tests by disease type along with vetted laboratory vendors to help physicians make informed decisions on the most personalized and effective ways to treat cancer for each patient.
Ontada is launched. Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer.
Amgen and McKesson launch strategic agreement to advance cancer innovation in communities

McKesson announces that it is participating in Phase II of the Friends of Cancer Research (Friends) Real-World Evidence (RWE) pilot project to advance the understanding and inform future uses of RWE

Providers using iKnowMed EHR are eligible for incentive payments under Merit-Based Incentive Payments System (MIPS)
McKesson launches Data, Evidence and Insights, a part of the new McKesson Life Sciences portfolio designed to support biopharma clinical and commercial strategy development

McKesson expands its agreement with the NCCN, adding five additional disease states to Value Pathways
For the first time, real-world data (RWD) from McKesson’s iKnowMed EHR was part of a regulatory approval in oncology. McKesson's real-world evidence study was key in the FDA's approval of a new treatment for a rare skin cancer called metastatic Merkel Cell Carcinoma (mMCC)

McKesson purchases Vantage Oncology, LLC, a leading national provider of radiation oncology, medical oncology, and integrated cancer care, and Biologics, Inc., an oncology pharmacy services company, creating a more expansive suite of offerings in the oncology space
McKesson announces a comprehensive solution to support community-based oncology practices participating in The Center for Medicare and Medicaid Innovation’s (CMMI) Oncology Care Model (OCM)

Clear Value Plus is introduced, presenting Value Pathways powered by NCCN and NCCN Guidelines within the clinical workflow. This move offers integrated financial information, real-time reporting and benchmarking, and the ability to interface with an EHR
The first conversion of an iKnowMed Generation 1 customer to the iKnowMed Generation 2 platform occurs